Gadolinium-160 - China Isotope Development

Gadolinium-160 Target Material: A Game-Changer for Next-Generation Beta Therapy in Oncology

Industry NewsBy China Isotope Development 2025-12-28

Gadolinium-160 Target Material: A Game-Changer for Next-Generation Beta Therapy in Oncology BY Tao, Published Dec 28, 2025 Gadolinium-160 (Gd-160) is not a “therapy isotope” itself—it is a strategic stable target material that enables reliable reactor production of Terbium-161 (Tb-161), one of the most compelling next-generation radionuclides for targeted beta therapy and theranostics (therapy + imaging) in oncology. What makes this pathway special…

From Gd-160 to Tb-161: Revolutionizing Theranostic Applications in Nuclear Medicine

Industry NewsBy China Isotope Development 2025-12-28

From Gd-160 to Tb-161: Revolutionizing Theranostic Applications in Nuclear Medicine BY Tao, Published Dec 28, 2025 From the early days of Iodine-131 to the recent dominance of Lutetium-177 (177Lu177Lu), each generation of isotopes has pushed the boundaries of what is clinically possible. However, as we stand here in late 2025, reflecting on the…

Gadolinium-160: The Essential Precursor for Terbium-161 Production in Targeted Cancer Radiotherapy

Industry NewsBy China Isotope Development 2025-12-28

Gadolinium-160: The Essential Precursor for Terbium-161 Production in Targeted Cancer Radiotherapy BY Tao, Published Dec 28, 2025 Terbium-161 (Tb-161) is emerging as one of the most promising “next-step” therapeutic radionuclides for targeted radionuclide therapy (also called targeted radiotherapy or radioligand therapy) because it behaves chemically like the widely used Lutetium-177 (Lu-177), yet delivers additional ultra-short-range electron dose that…